Formycon's Stelara biosimilar — known as FYB202 — is set to be marketed in the US by partner Fresenius Kabi as Otulfi (ustekinumab-aauz)...
6 months ago

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) today reported on the Group's business development and financial results for...
1 month ago

Formycon reiterates 2025 guidance, expects stronger second half ... © Reuters. ... Investing.com -- Formycon AG (ETR:FYB) reported first-half...
4 weeks ago

Three players in the biosimilar space have already sparked hope for the new year, with each having big business or regulatory announcements.
7 months ago

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Formycon AG today and set a price target of €48.00. Yi Chen has given his Buy...
1 week ago

Germany's Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206.
6 months ago

Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival...
6 months ago

The commercialisation agreements for the biosimilar to aflibercept (Eylea) cover Israel, major parts of Europe and the Asia-Pacific Region.
7 months ago

Otulfi is indicated for the treatment of moderately to severely active Crohn's disease and ulcerative colitis in adult patients.
5 months ago

Formycon ( ETR:FYB ) Full Year 2024 Results Key Financial Results Revenue: €69.7m (down 10% from FY 2023). Net loss...
5 months ago